Grifois
GRFS
Market cap $6.18B

9.08 USD

-0.06

0.66%

At close Jul 3, 4:00 PM EDT

1 day

-0.66%

5 days

3.06%

1 month

8.87%

3 months

27.71%

6 months

17.46%

Year to date

20.42%

1 year

36.75%

5 years

-52.34%

10 years

-40.77%

About: Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Employees: 23,822

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,310 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

25% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 5 (+1) [Q1 2025]

24% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 45

1.29% more ownership

Funds ownership: 54.33% [Q4 2024] → 55.62% (+1.29%) [Q1 2025]

2% less capital invested

Capital invested by funds: $1.06B [Q4 2024] → $1.03B (-$22M) [Q1 2025]

7% less funds holding

Funds holding: 153 [Q4 2024] → 142 (-11) [Q1 2025]

20% less call options, than puts

Call options by funds: $1.2M | Put options by funds: $1.49M

21% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 24

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$10.30

13%

upside

Avg. target

$10.30

13%

upside

High target

$10.30

13%

upside

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

JP Morgan

James Gordon

13%upside

$10.30

Neutral

Maintained

17 Jun 2025

See Analyst Rankings

Financial journalist opinion

XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology

Freising, Germany, June 10, 2025 — XL-protein GmbH, a pioneer in the area of biopolymers for pharmacokinetic optimization, announced today that it has entered into a worldwide License, Development and Commercialization Agreement with Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, for a novel, long-acting biopharmaceutical product.

XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology

Zacks Investment Research

Grifols (GRFS) Is Up 2.47% in One Week: What You Should Know

Does Grifols (GRFS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Grifols (GRFS) Is Up 2.47% in One Week: What You Should Know

Zacks Investment Research

Is Grifols (GRFS) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Grifols (GRFS) Stock Undervalued Right Now?

Zacks Investment Research

GRFS vs. STVN: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?

GRFS vs. STVN: Which Stock Is the Better Value Option?

Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting

NEW YORK--(BUSINESS WIRE)--Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today announced that it sent a letter to the Grifols Board of Directors (the “Board”) expressing Mason's support for the Company's recommended slate of director candidates for election at the Ordinary General Shareholders' Meeting to be held on June 4 and 5, 2025. T.

Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting

US court finds enough evidence to proceed with Grifols lawsuit against Gotham City

A New York court found enough evidence to continue with the defamation lawsuit filed by Spanish pharmaceutical company Grifols against short seller Gotham City Research, Grifols said in a statement on Friday.

US court finds enough evidence to proceed with Grifols lawsuit against Gotham City

Zacks Investment Research

ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?

At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.

ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?

Grifols: If This Works Out, It Has Massive Upside

Grifols offers compelling long-term upside, with potential returns exceeding 200% as the company recovers and grows earnings. Recent Q1 2025 results confirm strong operational recovery: top-line growth, improved margins, and significant debt reduction, supporting my continued conviction. The primary risk is high leverage, but ongoing cash flow improvements and no dividend payout allow to focus on deleveraging, with dividend restoration likely by 2026.

Grifols: If This Works Out, It Has Massive Upside

Zacks Investment Research

GRFS or NBIX: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Grifols (GRFS) and Neurocrine Biosciences (NBIX). But which of these two stocks presents investors with the better value opportunity right now?

GRFS or NBIX: Which Is the Better Value Stock Right Now?

Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript

Grifols, S.A. (NASDAQ:GRFS ) Q1 2025 Earnings Conference Call May 12, 2025 12:30 PM ET Company Participants Danny Segarra - VP, IR and Sustainability Nacho Abia - CEO Rahul Srinivasan - CFO Roland Wandeler - President Biopharma Conference Call Participants Charles Pitman - Barclays Alvaro Lenze - Alantra Equities Jaime Escribano - Banco Santander Guilherme Sampaio - CaixaBank Danny Segarra Hello, everyone.

Grifols, S.A. (GRFS) Q1 2025 Earnings Conference Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™